Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)

Next Previous
Trial Profile

A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Atherosclerosis; Low HDL cholesterol
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Resverlogix Corporation

Most Recent Events

  • 22 Jun 2010 Data presented at the European Atherosclerosis Society Congress, according to a Resverlogix media release.
  • 03 Feb 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
  • 29 Sep 2009 Status changed from recruiting to completed, according to a Resverlogix media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top